WO2008156069A1 - Screening method for antibody and antibody obtained by the method - Google Patents

Screening method for antibody and antibody obtained by the method Download PDF

Info

Publication number
WO2008156069A1
WO2008156069A1 PCT/JP2008/061017 JP2008061017W WO2008156069A1 WO 2008156069 A1 WO2008156069 A1 WO 2008156069A1 JP 2008061017 W JP2008061017 W JP 2008061017W WO 2008156069 A1 WO2008156069 A1 WO 2008156069A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
production
screening method
specific surface
Prior art date
Application number
PCT/JP2008/061017
Other languages
French (fr)
Japanese (ja)
Inventor
Tadao Okamoto
Masami Miura
David King
Asna Masood
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of WO2008156069A1 publication Critical patent/WO2008156069A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

It is intended to provide a novel screening method for an antibody, an antibody obtained by the method and a pharmaceutical composition containing the antibody as an active ingredient. The screening method for an antibody against a B-cell specific surface antigen, comprising the steps of: i) adding an antibody against a B-cell specific surface antigen to B cells; ii) confirming that IL-6 production by B cells is changed and/or confirming that IL-10 production by B cells is changed. The antibody which is against a B-cell specific surface antigen and has an action of changing IL-6 production by B cells and/or has an action of changing IL-10 production by B cells. The pharmaceutical composition containing the antibody as an active ingredient.
PCT/JP2008/061017 2007-06-18 2008-06-17 Screening method for antibody and antibody obtained by the method WO2008156069A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160531A JP2010222255A (en) 2007-06-18 2007-06-18 Method for screening antibody and antibody obtained by the method
JP2007-160531 2007-06-18

Publications (1)

Publication Number Publication Date
WO2008156069A1 true WO2008156069A1 (en) 2008-12-24

Family

ID=40156228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061017 WO2008156069A1 (en) 2007-06-18 2008-06-17 Screening method for antibody and antibody obtained by the method

Country Status (3)

Country Link
JP (1) JP2010222255A (en)
TW (1) TW200920399A (en)
WO (1) WO2008156069A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239181A (en) * 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Methods for identifying immunobinders of cell-surface antigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526501A (en) * 2002-02-21 2005-09-08 デューク・ユニヴァーシティ Reagents and therapeutic methods for autoimmune diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526501A (en) * 2002-02-21 2005-09-08 デューク・ユニヴァーシティ Reagents and therapeutic methods for autoimmune diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROSS J.T. ET AL.: "The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus", INFLAMM. RES., vol. 48, no. 5, 1999, pages 255 - 261, XP002506261 *
EDWARDS J.C. ET AL.: "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N. ENGL. J. MED., vol. 350, no. 25, 2004, pages 2572 - 2581, XP008067127 *
FILLATREAU S. ET AL.: "B cells regulate autoimmunity by provision of IL-10", NAT. IMMUNOL., vol. 3, no. 10, 2002, pages 944 - 950 *
OTSUKA J. ET AL.: "Jiko Men'eki Shikkan o Megutte SLE ni Okeru B-Saibo Kogen Juyotai Signal Dentatsu Ijo", CLINICAL IMMUNOLOGY, vol. 40, no. 1, 2003, pages 43 - 49 *
SATO S.: "Jiko Kotai no Sansei Kijo to Sono Byogensei Zenshinsei Kyohisho ni Okeru B-Saibo Ijo to Jiko Kotai Sansei", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 29, no. 2, 2006, pages 73 - 84 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239181A (en) * 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Methods for identifying immunobinders of cell-surface antigens
US8465937B2 (en) 2009-02-24 2013-06-18 ESBATech, an Alcon Biomedical Research Unit, LLC Methods for identifying B-clones which bind cell-surface antigens
US9221905B2 (en) 2009-02-24 2015-12-29 Esbatech, An Alcon Biomedical Research Unit Llc Methods for producing immunobinders of cell-surface antigens
US9908940B2 (en) 2009-02-24 2018-03-06 Esbatech, An Alcon Biomedical Research Unit Llc Humanized immunobinders of cell-surface antigens

Also Published As

Publication number Publication date
JP2010222255A (en) 2010-10-07
TW200920399A (en) 2009-05-16

Similar Documents

Publication Publication Date Title
WO2009036281A3 (en) Bortezomib and process for producing same
EP1740156B8 (en) Method for the production of an abuse-proof, solid form of administration
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
WO2010031720A3 (en) Novel antibody formulation
MX336682B (en) Antibodies against human csf-1r and uses thereof.
MX356337B (en) Antibodies against human csf-1r and uses thereof.
WO2007093627A3 (en) Biocidal composition
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
WO2007117490A3 (en) Antibody purification
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
WO2008083950A3 (en) Spirocyclic tetronic acid derivatives
WO2007082693A3 (en) Improved enzyme formulations for animal feed
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2010009879A3 (en) Methods for producing paricalcitol
WO2011131368A3 (en) A method of preparing an oral dosage form comprising fingolimod
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
WO2012017322A3 (en) Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2011129562A3 (en) Method for the mass production of silver nanoparticles having a uniform size
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2012148148A3 (en) Novel zinc azide complex and a process for preparing tetrazole derivatives using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777255

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777255

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP